Ospemifene
[Z-2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol]
is a third-generation oral, non-estrogen and selective estrogen receptor
modulator (SERM), with a unique set of tissue-specific estrogenic
agonist/antagonist effects. Ospemifene is the first non-estrogen treatment
approved for moderate to severe dyspareunia in women with menopause-related
vulvar and vaginal atrophy (VVA) [1]. Ospemifene was first identified as one of the main metabolites of Toremifene.
Ospemifene: 2D and 3D Structure |
Dyspareunia is pain during sexual intercourse - encountered by some women, generally those who are post-menopausal. Ospemifene acts similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia.
Chemically,
Ospemifene has triarylethylene framework, a structural variant of the estrogen
diethystilbesterol that forms the backbone of a number of non-steroidal
estrogen agonists in some tissues as well as antagonists in other tissues (also
known as SERMs). It has proven as a novel SERM that acts as agonist by
mimicking estrogen in brain, bone and vagina and acts as an antagonist in
uterus and breasts. Its biological actions are mediated through binding to
estrogen receptors resulting in the activation of estrogenic pathways in some
tissues (agonism) and blockade of estrogenic pathways in others (antagonism).
The
efficacy and safety of this drug was demonstrated in nine clinical trials with
about 2000 participants, and based on the results was Ospemifene approved by
the US FDA in February 2013 for the treatment of moderate to severe dyspareunia.
Recent reports have also shown its bioactivity in the prevention of
osteoporosis and as an anti-breast cancer agent.
Ospemifene
(Tradename: Osphena)
is once-a-day oral pill with recommended dosage of 60 mg/day, to be taken with
meals. The treatment duration should be the shortest possible, taking into
account treatment goals and risks to the individual patient, with periodic
re-evaluation.
Interaction of Ospemifene with estrogen receptors:
The interaction of Ospemifene with estrogen
receptors (ERs) was evaluated by studying the ability of the compound to
compete with 17β-[3H]E2
for binding to purified recombinant human ERα and ERβ proteins and by
comparing that to unlabeled estradiol. Ospemifene displaced estradiol in a
concentration-dependent manner, and IC50 values of 827 and 1633 nM were obtained for ER-α and -β, respectively. The IC50 values
for 17β-E2 under
the corresponding conditions were 6.8 and. 9.1 nM. The relative binding
affinities of Ospemifene calculated from these values were 0.8% and 0.6% for ERα and ERβ, respectively [3].
Ospemifene Synthesis
Identification:
1H NMR (Estimated) for Ospemifene |
Sideeffects:
References:
1. McCall, J. L.; et. al. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol 2010, 6(6), 773-779.
2. Eklund, L.; et. al. New processes for producing benzophenone derivatives. WO2011089385A1
3. Qu, Q.; et. al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000, 141(2), 809-820.
3. Qu, Q.; et. al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000, 141(2), 809-820.